Kat Murti of Students for Sensible Drug Policy

Kat Murti, Executive Director with Students for Sensible Drug Policy

Kat Murti is the Executive Director of Students for Sensible Drug Policy (SSDP), the world's largest youth-led grassroots organization dedicated to ending the War on Drugs and advancing drug policies rooted in science, compassion, human rights, and individual liberty. She has been a leader within SSDP since joining the University of California, Berkeley chapter in 2009, serving in numerous leadership roles before being named Executive Director.

A longtime advocate for criminal justice reform, Kat has worked on cannabis legalization campaigns, drug policy reform initiatives, and public education efforts at the local, state, federal, and international levels. She previously served as the Bay Area Regional Director for California's Proposition 19 campaign to legalize adult-use cannabis and has also worked with organizations including the Criminal Justice Policy Foundation, the Cato Institute, and the Mercatus Center at George Mason University.

Beyond SSDP, Kat is the co-founder and Executive Director of Feminists for Liberty, where she advocates for individual rights, equal opportunity, and limited government through a libertarian perspective. Her work has earned national recognition, including being named one of Red Alert Politics' "30 Under 30" and one of the "40 Under 40 Outstanding BIPOC Leaders in Drug Policy." She holds a Bachelor's degree in Political Science from the University of California, Berkeley, and is also a graduate of Oaksterdam University.

In this episode of the How You Doing Show, Kat joins us from Arlington, Virginia, during the historic DEA hearing on the proposed federal rescheduling of cannabis. Together, we discuss why moving cannabis from Schedule I to Schedule III is only one step toward meaningful reform, the continued incarceration of non-violent cannabis offenders, the lasting consequences of prohibition, and why grassroots activism remains essential in shaping the future of American drug policy.